2017 price target is $1.25, analysis shows me we should reach 1.25 or higher in the next 12 months. I had to sell $RNVA for +10% here as this play is too good to pass up. Company is EXTREMELY undervalued given the things in the work for 2017. Several patents, topical Viagra in the works, entrance into the Medical Marijuana sector...Company should also fair well and benefit from the repeal of Obamacare. This will be one to watch, lock in profits don't get emotional. Good money to be made long term.